Blue Jet Healthcare Share Price Hits Lower Circuit of 10% After Q1FY26 Results

As of 2:49 PM on July 22, 2025, Blue Jet Healthcare share price hit the lower circuit of 10%, drawing attention despite the company announcing strong Q1 FY26 results earlier in the day. 

Here is a breakdown of the quarterly performance and relevant developments.

Blue Jet Healthcare Q1FY26 Results

Blue Jet Healthcare reported revenue from operations of ₹3,548 million for the quarter ended June 30, 2025, reflecting a YoY increase of 117.8% compared to ₹1,629 million in Q1 FY25. On a sequential basis, revenue rose by 4.2% from ₹3,404 million in Q4 FY25.

The company’s EBITDA stood at ₹1,210 million, marking a YoY growth of 173.3% over ₹443 million reported in the same quarter last year. However, EBITDA fell by 13.6% on a QoQ basis due to a drop in gross margin, which declined to 48.4% in Q1FY26 from 54.7% in the previous quarter.

EBITDA And PAT Margins Show Mixed Trend

EBITDA margin for Q1 FY26 came in at 34.1%, rising 693 basis points from 27.2% in Q1 FY25. However, this was lower than the 41.1% margin achieved in Q4 FY25, indicating a QoQ drop of 701 basis points.

Profit after tax for the quarter stood at ₹912 million, up 141.3% YoY from ₹378 million. Compared to ₹1,101 million in the previous quarter, PAT declined by 17.2%, primarily due to the dip in gross margin and reduced inventory absorption.

Factors Behind Sequential Decline

Despite the annual growth, the company’s QoQ performance took a hit. The management attributed this to changes in product mix and lower inventory levels, leading to a drop in overhead absorption. Gross margin slipped from 54.7% in Q4 FY25 to 48.4% in Q1 FY26, impacting overall profitability.

Read More: Back-to-Back Upper Circuits: Colab Platforms Share Price Hits Upper Circuit of 2%! 

About Blue Jet Healthcare

Blue Jet Healthcare operates as a contract development and manufacturing organisation (CDMO) and specialises in contrast media intermediates and high-intensity sweeteners. The company supplies critical intermediates to global players such as GE Healthcare, Guerbet, and Bracco, and caters to FMCG majors like Colgate Palmolive and Unilever.

Conclusion

Blue Jet Healthcare share price declined and hit the lower circuit as of July 22, 2025, reflecting investor reaction to the sequential drop in EBITDA margins. Despite strong year-on-year growth, the dip in profitability and gross margin appears to have weighed on market sentiment.

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in securities are subject to market risks. Read all related documents carefully before investing.